JP2021534129A5 - - Google Patents
Info
- Publication number
- JP2021534129A5 JP2021534129A5 JP2021506964A JP2021506964A JP2021534129A5 JP 2021534129 A5 JP2021534129 A5 JP 2021534129A5 JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021534129 A5 JP2021534129 A5 JP 2021534129A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- inhibitor
- combination according
- ret
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717480P | 2018-08-10 | 2018-08-10 | |
| US62/717,480 | 2018-08-10 | ||
| US201862735730P | 2018-09-24 | 2018-09-24 | |
| US62/735,730 | 2018-09-24 | ||
| PCT/US2019/045919 WO2020033838A2 (en) | 2018-08-10 | 2019-08-09 | Treatment of egfr-mutant cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534129A JP2021534129A (ja) | 2021-12-09 |
| JP2021534129A5 true JP2021534129A5 (enExample) | 2022-08-17 |
| JP7490635B2 JP7490635B2 (ja) | 2024-05-27 |
Family
ID=69415686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506964A Active JP7490635B2 (ja) | 2018-08-10 | 2019-08-09 | Ｅｇｆｒ変異がんの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210308134A1 (enExample) |
| EP (1) | EP3833372A4 (enExample) |
| JP (1) | JP7490635B2 (enExample) |
| CN (1) | CN112703014A (enExample) |
| WO (1) | WO2020033838A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| WO2021243192A1 (en) * | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CR20220666A (es) * | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| US20230321098A1 (en) * | 2020-08-25 | 2023-10-12 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN113143931A (zh) * | 2021-04-16 | 2021-07-23 | 南方医科大学 | 甲磺酸奥西替尼在制备寻常型银屑病治疗药物中的应用 |
| CN116440136B (zh) * | 2023-04-17 | 2024-02-09 | 浙江大学智能创新药物研究院 | 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ｒｅｔ調節剤の開発のための化合物および方法 |
| WO2007087245A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Ret tyrosine kinase inhibition |
| WO2009003136A1 (en) | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| WO2013018882A1 (ja) | 2011-08-04 | 2013-02-07 | 独立行政法人国立がん研究センター | Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法 |
| WO2013028817A1 (en) | 2011-08-23 | 2013-02-28 | Foundation Medicine , Inc. | Novel kif5b-ret fusion molecules and uses thereof |
| WO2013077921A2 (en) * | 2011-09-02 | 2013-05-30 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| JPWO2014017491A1 (ja) | 2012-07-26 | 2016-07-11 | 国立研究開発法人国立がん研究センター | Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子 |
| EP3037547A1 (en) | 2013-08-20 | 2016-06-29 | National Cancer Center | New fusion gene detected in lung cancer |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| US10576085B2 (en) * | 2016-04-01 | 2020-03-03 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| EP3641776B1 (en) | 2017-06-23 | 2023-10-18 | San Diego State University Research Foundation | Atropisomerism for enhanced kinase inhibitor selectivity |
| CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| ES3074838T3 (es) | 2017-07-07 | 2026-07-23 | Medicover Public Co Ltd | Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación de biomarcadores tumorales |
| RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
-
2019
- 2019-08-09 EP EP19847106.2A patent/EP3833372A4/en not_active Withdrawn
- 2019-08-09 WO PCT/US2019/045919 patent/WO2020033838A2/en not_active Ceased
- 2019-08-09 US US17/267,149 patent/US20210308134A1/en not_active Abandoned
- 2019-08-09 CN CN201980060618.8A patent/CN112703014A/zh active Pending
- 2019-08-09 JP JP2021506964A patent/JP7490635B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor | |
| JP7304629B2 (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| JP2024133475A5 (enExample) | ||
| JP2011511071A5 (enExample) | ||
| JP2024501471A5 (enExample) | ||
| US20240229156A1 (en) | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles | |
| JP2023530351A5 (enExample) | ||
| JP2017533963A5 (enExample) | ||
| IL255312B (en) | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist | |
| JP2013507415A5 (enExample) | ||
| JP2017529382A5 (enExample) | ||
| JP2018534288A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2024533423A (ja) | 薬学的組成物およびその使用 | |
| JP2018516936A5 (enExample) | ||
| JP2022533981A5 (enExample) | ||
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| TW202332444A (zh) | 用於治療癌症之醫藥組成物 | |
| JP2023531675A5 (enExample) | ||
| WO2023114984A1 (en) | Tead inhibitors and uses thereof | |
| WO2023235716A2 (en) | Cancer treatment using topoisomerase i inhibitors and plk1 inhibitors | |
| US20250032495A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | |
| JP2023531930A5 (enExample) | ||
| Ohno | Treatment of chronic myeloid leukemia with imatinib mesylate |